Oral Immunization with Recombinant Lactobacillus Casei Displayed AHA1-CK6 and VP2 Induces Protection Against Infectious Pancreatic Necrosis in Rainbow Trout (oncorhynchus Mykiss).

Yaping Chen,Xiaojing Hua,Xuanyu Ren,Kexin Duan,Shuai Gao,Jinhui Sun,Ying Feng,Ying Zhou,Xin Guan,Dechuan Li,Na Wang,Jiahui Li,Jiawei Yang,Dong Xia,Wen Shi,Min Liu
DOI: https://doi.org/10.1016/j.fsi.2020.03.001
IF: 4.622
2020-01-01
Fish & Shellfish Immunology
Abstract:Infectious pancreatic necrosis virus (IPNV) primarily infects larvae and young salmonid with serious economic losses, which causes haemorrhage and putrescence of hepatopancreas. To develop a more effective oral vaccine against IPNV infection, the aeromonas hydrophila adhesion (AHA1) gene was used as a targeting molecule for intestinal epithelial cells. A genetically engineered Lactobacillus casei (pPG-612-AHA1-CK6-VP2/L. casei 393) was constructed to express the AHA1-CK6-VP2 fusion protein. The expression of interest protein was confirmed by western blotting and the immunogenicity of pPG-612-AHA1-CK6-VP2/L. casei 393 was evaluated. And the results showed that more pPG-612-AHA1-CK6-VP2/L. casei 393 were found in the intestinal mucosal surface of the immunized group. The Lactobacillus-derived AHA1-CK6-VP2 fusion protein could induce the production of serum IgM and skin mucus IgT specific for IPNV with neutralizing activity in rainbow trouts. The levels of IL-1β, IL-8 and TNF-α isolated from the lymphocytes stimulated by AHA1-CK6-EGFP produced were significantly higher than EGFP group. For transcription levels of IL-1β, IL-8, CK6, MHC-II, Mx and TNF-1α in the spleen, the result indicated that the adhesion and target chemokine recruit more immune cells to induce cellular immunity. The level of IPNV in the immunized group of pPG-612-AHA1-CK6-VP2/L. casei 393 was significantly lower than that in the control groups. These data indicated that the adhesion and target chemokine could enhance antigen delivery efficiency, which provides a valuable strategy for the development of IPNV recombination Lactobacillus casei oral vaccine in the future.
What problem does this paper attempt to address?